CTLA4 and neoplasm: Vétizou and colleagues have studied another anti-tumor immunotherapy, which relies on the blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4), a major negative regulator of T cell activation against a variety of antigens including tumor-associated antigens.